News
Investors
Careers
Contacts
About Us
Our Mission & Vision
The Zevra Story
Leadership
Board of Directors
What We Do
Partnering
Patients & Caregivers
Clinical Trials
Expanded Access Policy
Niemann-Pick Disease Type C
Urea Cycle Disorders
Vascular Ehlers-Danlos
Sleep Disorders
Our Products
MIPLYFFA®
OLPRUVA®
AZSTARYS®
Our Pipeline
Pipeline
Clinical Trials
Publications & Presentations
Medical Literature
Medical Information
Investigator-Initiated Studies
News
Investors
Careers
Contacts
Home
>
Latest
>
Arimoclomol Safety Profile in the Treatment of Niemann-pick Disease Type C In a Real-world Setting: Long-term Safety Data from an Expanded Access Program in the United States
Arimoclomol Safety Profile in the Treatment of Niemann-pick Disease Type C In a Real-world Setting: Long-term Safety Data from an Expanded Access Program in the United States